Participant flow

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma · Source last updated 2011-10-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   VELCADE 1.3 mg/m\^2 administered by subcutaneous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.

   id

   FG000

   title

   VELCADE Subcutaneous

2. description

   VELCADE 1.3 mg/m\^2 administered by intravenous infusion on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.

   id

   FG001

   title

   VELCADE Intravenous

periods

1. milestones

   1. achievements

      1. comment

         One patient randomized and not dosed

         group Id

         FG000

         num Subjects

         148

      2. group Id

         FG001

         num Subjects

         74

      type

      STARTED

   2. achievements

      1. comment

         Completed 8 cycles

         group Id

         FG000

         num Subjects

         81

      2. comment

         Completed 8 cycles

         group Id

         FG001

         num Subjects

         39

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         67

      2. group Id

         FG001

         num Subjects

         35

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice